Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director · CHIEF TECHNOLOGY OFFICER | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,821,870 |
Ending reported balance
After 2026-08-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 7,363 · Balance 4,804,051 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-08-18 · Tax withholding · Disposed 1,778 · Balance 4,802,273 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-08-18 · Exercise / conversion · Acquired 5,525 · Balance 4,807,798 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-08-18 · Tax withholding · Disposed 1,346 · Balance 4,806,452 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 6,162 · Balance 4,812,614 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-08-18 · Tax withholding · Disposed 1,501 · Balance 4,811,113 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-08-18 · Exercise / conversion · Acquired 14,220 · Balance 4,825,333 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-08-18 · Tax withholding · Disposed 3,463 · Balance 4,821,870 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,189 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 7,363 · Balance 17,189 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,995 |
Reported balance
After 2026-08-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-18 · Exercise / conversion · Disposed 5,525 · Balance 34,995 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 63,688 |
Reported balance
After 2026-08-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-18 · Exercise / conversion · Disposed 6,162 · Balance 63,688 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 203,835 |
Reported balance
After 2026-08-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-18 · Exercise / conversion · Disposed 14,220 · Balance 203,835 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.
F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.
F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,008,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,797 | $5.53 | $9,937.41 |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,002,896 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,004,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 588 | $5.53 | $3,251.64 |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,997,330 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:22 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021857 · form4-08212024_100846.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,997,918 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · derivative · entry 9 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,718 Underlying: Common Stock · 3,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · derivative · entry 8 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,454 Underlying: Common Stock · 4,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · derivative · entry 7 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,218 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,093 | $5.96 | $6,514.28 |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · nonDerivative · entry 6 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,995,937 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,997,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,456 | $5.96 | $8,677.76 |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,993,347 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,994,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 588 | $5.96 | $3,504.48 |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,989,895 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014148 · form4-05222024_100556.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,990,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 22:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $5.87 | $117,400.00 |
DisclosureSEC source: 0001415889-24-011390 · form4-04232024_100439.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,988,502 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.75 to $5.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 09, 2024 Filed Apr 11, 2024 22:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 400 | $7.01 | $2,804.00 |
DisclosureSEC source: 0001415889-24-010714 · form4-04112024_100410.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,008,502 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. Read SEC document |
| April 09, 2024 Filed Apr 11, 2024 22:17 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 1,500 | $7.00 | $10,500.00 |
DisclosureSEC source: 0001415889-24-010714 · form4-04112024_100410.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,008,902 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. Read SEC document |
| March 19, 2024 Filed Mar 19, 2024 22:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $6.71 | $134,200.00 |
DisclosureSEC source: 0001415889-24-008641 · form4-03192024_100347.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,010,402 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.56 to $6.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 22:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $6.77 | $135,400.00 |
DisclosureSEC source: 0001415889-24-008641 · form4-03192024_100347.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,030,402 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 9,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007872 · form4-03132024_100322.xml · derivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,362 Underlying: Common Stock · 9,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,911 | $7.22 | $21,017.42 |
DisclosureSEC source: 0001415889-24-007872 · form4-03132024_100322.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,050,402 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 11, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:55 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 9,817 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-007872 · form4-03132024_100322.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,053,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 88,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007440 · form4-03082024_110327.xml · derivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,401 Underlying: Common Stock · 88,401 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 131,578 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007440 · form4-03082024_110327.xml · derivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,578 Underlying: Common Stock · 131,578 shares Expires 2034-03-06 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004899 · form4-02222024_100239.xml · derivative · entry 3 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,199 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 588 | $8.38 | $4,927.44 |
DisclosureSEC source: 0001415889-24-004899 · form4-02222024_100239.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,043,496 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004899 · form4-02222024_100239.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,044,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 22:35 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $9.43 | $188,600.00 |
DisclosureSEC source: 0001209191-23-059472 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,042,103 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.26 to $9.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $6.03 | $120,600.00 |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,762,103 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.88 to $6.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · derivative · entry 7 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,179 Underlying: Common Stock · 7,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · derivative · entry 6 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,180 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,431 | $5.98 | $14,537.38 |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,782,103 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,784,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 772 | $5.98 | $4,616.56 |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,777,171 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056353 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,777,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 14, 2023 Filed Nov 28, 2023 01:48 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GiftCommon Stock | 1,700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056732 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,062,103 Read SEC document |
| October 19, 2023 Filed Oct 24, 2023 00:36 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $4.80 | $96,000.00 |
DisclosureSEC source: 0001209191-23-053410 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,775,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 22:27 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $6.49 | $129,800.00 |
DisclosureSEC source: 0001209191-23-050201 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,795,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.40 to $6.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $8.07 | $161,400.00 |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,815,962 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.83 to $8.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 7,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · derivative · entry 7 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,542 Underlying: Common Stock · 7,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · derivative · entry 6 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,161 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,868 | $8.46 | $24,263.28 |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,835,962 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 7,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,838,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 772 | $8.46 | $6,531.12 |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,831,467 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:08 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046824 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,832,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 22:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $8.76 | $175,200.00 |
DisclosureSEC source: 0001209191-23-042952 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,830,258 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.65 to $8.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 22:29 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $8.18 | $163,600.00 |
DisclosureSEC source: 0001209191-23-038904 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,850,258 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.02 to $8.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $7.19 | $143,800.00 |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · nonDerivative · entry 5 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,870,258 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.96 to $7.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · derivative · entry 7 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,905 Underlying: Common Stock · 4,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · derivative · entry 6 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,142 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.